Author information:
(1)Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, 
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical 
School, Boston, Massachusetts.
(2)Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, 
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical 
School, Boston, Massachusetts. paul_richardson@dfci.harvard.edu.